UNLIMITED TURBO SHORT - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 09:21:02 01/07/2024 BST | ||
| 2.34 EUR | -2.09% |
|
| Current month | -1.24% | ||
| 1 month | -2.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 2.34 | -2.09% |
| 28/06/24 | 2.39 | 0.00% |
| 27/06/24 | 2.39 | +3.46% |
| 26/06/24 | 2.31 | -0.43% |
| 25/06/24 | 2.32 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update July 01, 2024 at 09:21 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PN78UK |
| ISIN | DE000PN78UK9 |
| Date issued | 08/09/2023 |
| Strike | 66.96 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.85 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.52 € |
|---|---|
| Lowest since issue | 0.65 € |
| Spread | 0.01 € |
| Spread % | 0.43% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.53
USD
Average target price
53.19
USD
Spread / Average Target
+28.09%
- Stock Market
- Certificates
- Certificat
